High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study
Authors Lin TK, Liou YS, Lin CH, Chou P, Jong GP
Received 1 July 2017
Accepted for publication 14 December 2017
Published 18 January 2018 Volume 2018:10 Pages 159—165
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Irene Petersen
Tsung-Kun Lin,1,2 Yi-Sheng Liou,3,4 Ching-Heng Lin,5 Pesus Chou,2 Gwo-Ping Jong6
1Department of Pharmacy, Taoyuan Armed Forces General Hospital, Taoyuan, 2Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, 3Department of Family Medicine and Geriatrics, Taichung Veteran General Hospital, Taichung, 4School of Public Health, National Defense Medical Center, Taipei, 5Department of Medical Research, Taichung Veterans General Hospital, Taichung, 6Division of Internal Cardiology, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, Taiwan, Republic of China
Background: Statins have been linked to new-onset osteoporotic fractures (NOFs), and different statins may alter the risk for the development of NOFs.
Aim: In this study, we investigated the association between different statins and the development of NOFs.
Patients and methods: This was a longitudinal cohort study performed using data from claim forms submitted to the Taiwan Bureau of National Health Insurance, including case patients with NOFs from January 2004 to December 2013 and non-NOF subjects. We estimated the hazard ratios (HRs) of NOFs associated with statin use. Nonuser subjects served as the reference group.
Results: A total of 44,405 patients with NOFs were identified from among 170,533 patients with hyperlipidemia during the study period. The risk of developing NOFs after adjusting for age, sex, comorbidities, and concurrent medication use was lower among users of atorvastatin (HR, 0.77; 95% CI, 0.71–0.84) and rosuvastatin (HR, 0.72; 95% CI, 0.64–0.81) than among simvastatin users. Lovastatin, pravastatin, fluvastatin, and pitavastatin were not associated with the risk of developing NOFs compared with simvastatin users.
Conclusion: This study supports previous reports regarding a beneficial effect of statin use and NOF risk, but not all statins. Patients taking atorvastatin or rosuvastatin were at lower risk of developing NOFs compared with simvastatin users during the 10-year follow-up. Other statins such as pravastatin, fluvastatin, lovastatin, and pitavastatin were not associated with NOFs. This study also highlighted that high-potency statin has a dose–response effect on lower NOF risk.
Keywords: statins, new-onset osteoporosis fracture, hyperlipidemia
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]